Cullinan Therapeutics (NasdaqGS:CGEM) 2026 Conference Transcript

Summary of Cullinan Therapeutics Conference Call Company Overview - Company: Cullinan Therapeutics (NasdaqGS: CGEM) - Date: February 19, 2026 - Event: Citi's Virtual Oncology Leadership Summit Key Points Oncology Pipeline Development - 2026 Significance: Cullinan Therapeutics anticipates multiple catalysts across its oncology pipeline, particularly for T-cell engagers CLN-978 and CLN-049 [6][72] - CLN-978: A CD19 by CD3 T-cell engager targeting autoimmune diseases with a global development program aimed at lupus, rheumatoid arthritis (RA), and Sjögren's disease. The molecule is noted for its high binding affinity and potential to replace monoclonal antibodies [7][8] - CLN-049: A FLT3 x CD3 T-cell engager for acute myeloid leukemia (AML), presenting a first-in-class opportunity. The company aims to transition from dose escalation to dose expansion and is utilizing Fast Track designation from the FDA to select a recommended phase II dose [9][11] Clinical Data and Efficacy - CLN-049 Efficacy: Presented compelling monotherapy efficacy data at ASH 2025, with a complete response rate of approximately 30% and durable responses observed in patients, including those with P53 mutations [20][41] - Safety Profile: The safety profile of CLN-049 is favorable, with a lower incidence of cytokine release syndrome (CRS) compared to other T-cell engagers [21][22] Market Opportunity - AML Market Size: Approximately 20,000 new AML cases annually in the US, with a significant relapse/refractory patient pool. The potential market for CLN-049 in this segment is estimated to be a billion-dollar opportunity, with further expansion into frontline settings potentially unlocking multi-billion dollar opportunities [57][58] Financial Position - Cash Reserves: As of December 2025, Cullinan reported over $430 million in cash, providing a runway into 2029 to support ongoing programs [15] Zipalertinib Development - Partnership with Taiho: Zipalertinib, an EGFR exon 20 tyrosine kinase inhibitor, is in collaboration with Taiho, which is completing a rolling NDA submission. The agreement includes a 50/50 profit share in the US and $130 million in regulatory milestones [12][61] - Market Potential: The annual diagnosis of exon 20 non-small cell lung cancer in the US is estimated at 3,000-5,000 patients, presenting a significant market opportunity [60] Future Milestones - Upcoming Data Releases: Data updates for CLN-049 are expected in the second half of 2026, with dose expansion cohorts planned for initiation in Q2 2026 [70][71] - Regulatory Pathway: The company is confident in pursuing accelerated approval pathways for both CLN-049 and zipalertinib, with clear development strategies outlined [46][48] Conclusion - 2026 Outlook: Cullinan Therapeutics is positioned for a transformative year with multiple catalysts across its oncology and autoimmune pipelines, aiming to create shareholder value through strategic advancements and regulatory approvals [72]